Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 11 new programs entered clinical trials in 2025. These 11 ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potentialUp to ...

HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilitiesBEIJING, Jan. 12, ...

Crane Harbor Acquisition Corp. II is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first approved drug. The company received notice from the U.S. Food and Drug ...

In a detailed memorandum submitted by industry body NASSCOM, the sector has sought higher tax deductions for new employment, ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, ...